TransCon aVEGF

REDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a clinical-stage biotechnology company advancing next-generation, long-acting ophthalmic therapeutics, today announced that members of its management team will participate in one-on-one investor meetings at the following upcoming investor conferences: Wells Fargo Virtual Private Biopharma SymposiumDate: November 4, 2026Location: Virtual Stifel 2026 Healthcare ConferenceDate: November 10, 2026Location: New York City LifeSci Capital ConferenceDate: November 16, 2026Location: London UBS Global Biopharma ConferenceDate: November 17, 2026Location: London Piper Sandler 38th Annual Healthcare ConferenceDate: December 1, 2026Location: New York City Investors interested in meeting with Eyconis should contact their representative at the applicable conference host. About Eyconis Eyconis, a clinical-stage biotechnology company, is advancing next-generation, long-acting ophthalmic therapeutics. Through an exclusive worldwide license in ophthalmology from Ascendis Pharma, Eyconis is utilizing the commercially validated TransCon® technology platform to develop therapies that have the potential to reduce treatment burden, optimize disease control, and improve visual outcomes in people with serious eye disease. Eyconis’ lead program, EYC-0305, is being developed as a long-acting anti-VEGF therapy for wet age-related macular degeneration, with potential applicability across other retinal diseases including diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. EYC-0305 is currently being evaluated in OVERTURE, a Phase 1b/2a clinical trial in treatment-naïve patients with wet age-related macular degeneration. Beyond EYC-0305, Eyconis is developing a broader pipeline of long-acting therapies across other ophthalmic indications with significant unmet need. For more information, visit www.eyconis.com. Ascendis Pharma and TransCon are trademarks owned by the Ascendis Pharma group. Contacts Investor ContactChris BrinzeyICR Healthcarechris.brinzey@icrhealthcare.com Media ContactBen ShannonICR Healthcareben.shannon@icrhealthcare.com